Loading...
XSWX
LONN
Market cap46bUSD
Sep 17, Last price  
545.00CHF
1D
1.23%
1Q
9.28%
Jan 2017
233.73%
IPO
427.69%
Name

Lonza Group AG

Chart & performance

D1W1MN
XSWX:LONN chart
P/E
P/S
5.83
EPS
Div yield, %
0.73%
Shrs. gr., 5y
-1.29%
Rev. gr., 5y
7.70%
Revenues
6.53b
-0.65%
2,285,000,0002,870,000,0002,937,000,0002,690,000,0002,680,000,0002,692,000,0003,925,000,0003,584,000,0003,640,000,0003,803,000,0004,132,000,0004,548,000,0005,542,000,0004,207,000,0004,508,000,0005,409,000,0006,223,000,0006,717,000,0006,574,000,0006,531,000,000
Net income
-275m
L
222,000,000301,000,000419,000,000159,000,000284,000,000154,000,000182,000,00087,000,000237,000,000277,000,000301,000,000726,000,000559,000,000645,000,000869,000,0002,944,000,0001,215,000,000654,000,000636,000,000-275,000,000
CFO
1.17b
-8.24%
425,000,000644,000,000175,000,000422,000,000502,000,000221,000,000710,000,000522,000,000483,000,000741,000,000752,000,000841,000,0001,082,000,000977,000,0001,136,000,0001,220,000,0001,039,000,0001,385,000,0001,274,000,0001,169,000,000
Dividend
May 12, 20265 CHF/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Related entities

Subsidiaries (14)
CAPSUGEL BELGIUM
CAPSUGEL FRANCE
LONZA FINANCE INTERNATIONAL NV
LONZA INDIA PRIVATE LIMITED
LONZA SALES AG
LONZA SWISS FINANZ AG
LONZA VERVIERS
CAPSUGEL HUNGARY KORLÁTOLT FELELŐSSÉGŰ TÁRSASÁG
CAPSUGEL ITALY SOCIETÀ A RESPONSABILITÀ LIMITATA
CAPSUGEL SPAIN SL
INNOVATIVE WATER CARE EUROPE SAS
INNOVATIVE WATER CARE LIMITED
LONZA BIOLOGICS PLC
MW ENCAP LIMITED

Key people

Independent member of Board · since 2013
Jean-Daniel Gerber
Independent member of Board · since 2011
Angelica Kohlmann
Independent Member of the Board · since 2018
Lead Independent Member of the Board · since 2019
Antonio Trius
Independent Member of Board · since 2013
Olivier Verscheure
Independent Member of the Board · since 2018
IPO date
Apr 03, 2002
Employees
17,896
Domiciled in
CH
Incorporated in
CH
Legal address
MUNCHENSTEINERSTR. 38
BASEL, BS 4052
CH
Headquarters
MÜNCHENSTEINERSTR. 38
BASEL, BS 4052
CH
Previous name
AXERA AG

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT